SHANGHAI, China--(Business Wire)--
Medicilon/MPI Preclinical Research-Shanghai has been recognized as an accredited
International Association for Assessment and Accreditation of Laboratory Animal
Care (AAALAC) facility. This accreditation further underscores the company`s
commitment to quality research. The AAALAC initiative was led by Lijie Fu, PhD,
Executive Vice President of Operations, a national returnee with substantial
industry, scientific and CRO experience.
"We recognized that full AAALAC certification is essential for establishing
credibility within the industry.We understand and appreciate the need for these
standards, and have been diligently working to achieve this goal.With our
dedicated leadership and this accreditation, we are now able to enhance our
capabilities to further meet the needs of our Sponsors," says Bill Parfet, MBA,
Chairman of the Board of Medicilon/MPI Preclinical Research-Shanghai, and
Chairman and CEO of MPI Research.
Full AAALAC accreditation is a reflection of high standards, accountability and
a commitment to animal welfare. It is recognized as a milestone and benchmark
for responsible and ethical laboratory animal care, and also sets standards for
veterinary medical care, occupational health and safety, and physical plant or
HVAC standards that equal or exceed many non-accredited Western institutions.
The company attributes the achievement of this certification to the dual efforts
of the dedicated scientific management team, led by Mingli Chen, MD, MS, DABT,
VP of Research, along with a multidisciplinary team provided by one of the
parent company`s, MPI Research. The team members from MPI Research accepted
long-term assignments in Shanghai to train the local staff in Good Laboratory
Practices (GLP) and AAALAC standards.
"We are fortunate to have such a knowledgeable and enthusiastic team bringing
our newly formed company up to the regulatory standards of the industry.We pride
ourselves in the excellence of work that we produce and appreciate the steps
that it takes to reach this level of quality," says Jintao Zhang, PhD, CEO of
Medicilon/MPI Preclinical Research- Shanghai. Dr. Zhang co-founded Medicilon
Shanghai, the second parent company of this joint venture, and served as its CEO
in 2008.
Medicilon/MPI Preclinical Research-Shanghai provides global pharmaceutical and
biotechnology companies with high quality preclinical drug discovery and
development studies in an Asian facility that meet worldwide regulatory
standards.
For further information on Medicilon/MPI Preclinical Research-Shanghai, visit
medicilon-mpi.com.
Medicilon/MPI Preclinical Research-Shanghai
Jintao Zhang, PhD, CEO
+ 86 21 31268381
info@medicilon-mpi.com
Copyright Business Wire 2009
